Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.71 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7514662 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL7514670 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| Bicarbonate SCHEMBL9520380 | 0.92 | CHRNB2 (0.62) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL3128193 | 0.86 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL3017778 | 0.86 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL621129 | 0.86 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL3020951 | 0.86 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL617909 | 0.86 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL10398580 | 0.86 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL617910 | 0.86 | CHRNB2 (0.68) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063021-B2 | Ketolide anti-infective compounds | KOSAN BIOSCIENCES INCORPORATED (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063021-B2 | Ketolide anti-infective compounds | KOSAN BIOSCIENCES INCORPORATED (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-08-20 | — | — | US | disclosed |
| EP-0299379-B1 | PENTADIENAMIDE PAF-ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1993-04-21 | — | — | EP | disclosed |
| US-4975438-A | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. (US) | 1990-12-04 | — | — | US | disclosed |
| US-4927838-A | CARDIOVASCULAR DISORDERS | HOFFMAN-LA ROCHE INC. (US) | 1990-05-22 | — | — | US | disclosed |
| US-4927826-A | Cycloproylpropenamides useful as platelet activing factor (PAF) antagonists | HOFFMAN-LA ROCHE INC. (US) | 1990-05-22 | — | — | US | disclosed |
| US-4916145-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 1990-04-10 | — | — | US | disclosed |
| EP-0299379-A1 | Pentadienamide PAF-antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1989-01-18 | — | — | EP | disclosed |
| US-4788206-A | CARDIOVASCULAR DISORDERS, PLATELETS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4786646-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | CYP2C8, CCR8, CXCL8 | CHRNB2 4739/4885CHRNA4 4732/4885MEN1 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.